Compare IDEXX Laboratories, Inc. (IDXX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Prospect Capital Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: IDEXX Laboratories, Inc. is far larger — about 40.5× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 21.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PSEC | |
|---|---|---|
Market Cap | $46.22B | $1.14B |
Sector | Health | Financials |
52-Week High | $766.68 | $3.05 |
52-Week Low | $526.44 | $2.11 |
Enterprise Value | $47.12B | — |
Dividend Yield | — | 21.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
PSEC trades at $2.285, down 0.22% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company shows mixed fundamentals, with a low P/B of 0.39 and recent earnings beats, but negative revenue and net income margins. Recent news includes a dividend increase announcement and the sale of Valley Electric for $328 million, signaling active portfolio management.
Outlook: PSEC offers a deep value proposition with its discount to book value and high yield, but significant risks persist from negative profitability and volatile revenue trends. Analyst sentiment is cautious, with a majority hold rating, reflecting concerns over sustained earnings and NAV stability amid ongoing dividend adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
